Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Appointments

866.588.2264

Request an Appointment

Questions

866.588.2264

Contact us with Questions

Expand Content

Clinical Trials

Huntington's Disease Clinical Trials

Refer to the questions below to learn more about our current Huntington's Disease clinical trials.

Do you or a family member have Huntington's Disease (HD)?

Cleveland Clinic is conducting a clinical research study to collect information and biological samples from HD patients and their family members to learn more about HD and to try to find new treatments for the disease.

Approximately 15,000 people are anticipated in this trial that is being conducted at approximately 200 research centers across the 30 countries.

Cleveland Clinic Main Campus (Cleveland, OH) and Cleveland Clinic Lou Ruvo Center for Brain Health (Las Vegas, NV) are participating in this research study.

The study involves yearly office visits with a neurologist and research personnel.

If you are interested in learning more about this trial, please contact study coordinator Suzanne Mazhuvanchery at 216.445.5637 or email cnrresearchreferrals@ccf.org and reference study: Enroll-HD.

You can also find additional information on this trial at:

Parkinson's Disease Clinical Trials

Refer to the questions below to learn more about our current Parkinson's Disease clinical trials.

Do you have Parkinson's Disease (PD) experience "OFF" time?

The Cleveland Clinic Main Campus is conducting a clinical research study to determine if an investigational drug, a fast-acting formulation of apomorphine that is placed under the tongue, is safe and effective in decreasing "OFF" time in PD patients already taking levodopa.

Approximately 126 patients are being recruited for this trial – 4 at the Cleveland Clinic Main Campus.

The study involves up to 13 visits to the Cleveland Clinic Main Campus over approximately 4.5 months.

Main Inclusion Criteria

  • At least 18 years of age with PD
  • On levodopa therapy with continued benefit
  • More than 2 hours "OFF" time per day

Main Exclusion Criteria

  • History malignant melanoma
  • Cankers or mouth sores
  • Previous treatment with neurosurgical procedures for PD or continuous subcutaneous apomorphine infusion; or Duodopa/Duopa

If you are interested in learning more about this trial, please contact study coordinator Alexandria Wyant at 216.444.1179 3 or email cnrresearchreferrals@ccf.org and reference study: CTH-300.

You can also find additional information on this trial at:

Are you over the age of 60 with a reduced smell but do NOT have Parkinson's Disease (PD)?

Cleveland Clinic's Main Campus is working with The Michael J Fox Foundation on a clinical research study called The Parkinson’s Progression Marker Initiative (PPMI). The goal of PPMI is to identify and assess biomarkers in people who are at risk to develop PD as well as those with typical PD symptoms. The PPMI project has various sub-studies, including one looking for non-PD patients with a reduced sense of smell.

While most people with a reduced sense of smell will not develop PD, the majority of PD patients do have reduced sense of smell. This loss of smell often begins several years prior to the onset of motor symptoms like tremor or stiffness.

You qualify to participate in this PPMI sub-study if you are over the age of 60 with a reduced sense of smell and no PD diagnosis.

The study involves up to 48 months of participation. There are approximately six visits in the first year and then a visit every 6 months until completion.

If you are interested in learning more about this trial, please contact study coordinator Jennifer Mule at 216.444.1134 or email cnrresearchreferrals@ccf.org and reference study: PPMI.

You can also find additional information on this trial at:

Do you have Parkinson's Disease (PD) and are considering deep brain stimulation (DBS) as a treatment option?

Cleveland Clinic Main Campus is recruiting for a clinical research study that being done to evaluate the safety and effectiveness of Boston Scientific’s implantable DBS system in advanced PD patients with levodopa-responsive PD that is not being adequately controlled by medication. The goal of this system is to improve the number of waking hours per day with good symptom control and no troublesome dyskinesia (involuntary movements).

Approximately 310 PD patients are being recruited for this trial with approximately ten (10) anticipated at the Cleveland Clinic Main Campus.

The study involves approximately 12 scheduled visits to the Cleveland Clinic Main Campus during Year 1with yearly visits through Year 5.

Main Inclusion Criteria (patients who may be eligible to participate)

  • Between the ages of 22-75
  • Diagnosed with PD at least five (5) years ago
  • Have symptoms of resting tremor (trembling or shaking), rigidity (stiffness) or bradykinesia (slowness of movement)
  • Willing to travel to CCF main campus for frequent visits

Main Exclusion Criteria (patients who may not be eligible to participate)

  • Ay medical or neurological condition that puts you at surgical risk
  • Any significant psychiatric condition
  • Current substance abuse

If you are interested in learning more about this trial, please contact study coordinator Alexandria Wyant at 216.444.1179. or email cnrresearchreferrals@ccf.org and reference study: INTREPID

You can also find additional information on this trial at:

You can also download our flyer below:

Intrepid

Do you have Parkinson's Disease and experience periods where your medication isn't working?

The Cleveland Clinic Main Campus is conducting a clinical research study to determine the effectiveness of an investigational drug, tozadenant, to decrease "OFF" time in PD patients already taking levodopa.

Approximately 450 are being recruited for this trial – 6 at Cleveland Clinic Main Campus.

The study involves 14 visits to the Cleveland Clinic Main Campus over approximately 1.5 years.

Main Inclusion Criteria

  • Between the ages of 30-80 with Parkinson's Disease for at least 3 years
  • On levodopa therapy at least 4 times per day with continued benefit
  • Currently taking a secondary Parkinson’s Disease medication ( ex. Amantadine)
  • At least 2.5 hours "OFF" time per day

Main Exclusion Criteria

  • History of surgical intervention for PD
  • Low blood pressure when standing up that requires medication
  • Known diagnosis of Malignant Melanoma

If you are interested in learning more about this trial, please contact study coordinator Yvette Pitchford at 216.445.7513 or email cnrresearchreferrals@ccf.org and reference study: TOZ-PD

You can also find additional information on this trial at:

Headache Clinical Trials

Refer to the information below to learn more about our current headache clinical trials.

Are you a working adult diagnosed with episodic migraine?

Cleveland Clinic's main campus is conducting a clinical research study to compare the effectiveness of an FDA approved medication, Treximet, vs. other standard Triptan medications for migraine management.

Approximately 60 patients will be enrolled into this study.

The study involves three (3) visits to the Cleveland Clinic Main Campus as well as phone calls with research personnel.

Main Inclusion Criteria

  • At least 18 years of age with migraine diagnosis before age 50
  • Migraines for at least one year
  • Currently employed and taking triptan medication, such as Imitrex, for migraine management

Main Exclusion Criteria

  • History of stroke, heart attack or uncontrolled high blood pressure
  • Allergy to aspirin or naproxen
  • Pregnant or nursing

If you are interested in learning more about this trial, please contact study coordinator Michael Zeleny at 216.445.1861 or email zelenym@ccf.org and reference study: Treximet.